Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.3 USD | +0.43% | +1.64% | +24.83% |
May. 08 | Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Business Summary
Number of employees: 99
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Grant
80.7
%
| 1 | 24.1 % | 2 | 80.7 % | +48.45% |
Antigen Tests Products
19.3
%
| 4 | 75.9 % | 0 | 19.3 % | -88.72% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 5 | 100.0 % | 2 | 100.0 % | -55.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Kelley
CEO | Chief Executive Officer | 52 | 20-08-31 |
Director of Finance/CFO | 51 | 21-12-31 | |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Emily Faucette
IRC | Investor Relations Contact | - | 20-12-31 |
- | - | ||
Matthew Pepe
HRO | Human Resources Officer | - | 21-04-30 |
Jill Green
LAW | General Counsel | - | 19-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Matthew Posard
BRD | Director/Board Member | 56 | 16-02-29 |
Randal Scott
BRD | Director/Board Member | 66 | 13-12-31 |
Kim Popovits
BRD | Director/Board Member | 65 | 20-07-30 |
Robert Kelley
CEO | Chief Executive Officer | 52 | 20-08-31 |
Heiner Dreismann
BRD | Director/Board Member | 69 | 23-05-18 |
Rustem Ismagilov
FOU | Founder | 50 | 13-06-25 |
Raymond Cheong
BRD | Director/Board Member | 42 | 20-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,822,153 | 1,670,630 ( 91.68 %) | 0 | 91.68 % |
Stock B | 0 | 29,863,674 | 0 | 0 |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+24.83% | 16.94M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TLIS Stock
- Company Talis Biomedical Corporation